Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration
| Autor: | Joyce Sprock, Michael J. Walsh, Neal R. Swerdlow, Jo Talledo, Juan L. Molina, Jairo Alberto Romero, Branko N. Huisa, Steven Huege, Lisa Delano-Wood, Gregory A. Light, Yash B. Joshi, Juliana Kotz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male medicine.medical_specialty Disease Neuropsychological Tests Placebo Article Cognition Double-Blind Method Event-related potential Alzheimer Disease Memantine Internal medicine medicine Humans Prepulse inhibition Aged business.industry General Neuroscience General Medicine Therapeutic trial Psychiatry and Mental health Clinical Psychology Female Geriatrics and Gerontology business Neurocognitive Excitatory Amino Acid Antagonists Biomarkers medicine.drug |
| Zdroj: | J Alzheimers Dis |
| ISSN: | 1875-8908 |
| Popis: | Memantine’s benefits in Alzheimer’s disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual’s clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|